ArticleAntimicrobial agents and chemotherapy2002
Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Persistent Borrelia burgdorferiClinical microbiology reviews · 2022Review
- Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.Drug design, development and therapy · 2016Article
- Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.Antimicrobial agents and chemotherapy · 2014Article
- Intraarticular corticosteroids in refractory childhood Lyme arthritis.Rheumatology international · 2014Article
- Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability.Journal of clinical microbiology · 2013Article
- Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.The Journal of clinical investigation · 2012Article
- Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.Antimicrobial agents and chemotherapy · 2010Article
- Antibiotic treatment of animals infected with Borrelia burgdorferi.Clinical microbiology reviews · 2009Review
- Persistent arthritis in Borrelia burgdorferi-infected HLA-DR4-positive CD28-negative mice post-antibiotic treatment.Arthritis and rheumatism · 2008Article
- Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector.Infection and immunity · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftriaxone is highly effective clinically in patients with Lyme disease. We studied a representative invasive human isolate of Borrelia burgdorferi for which the MBC of ceftriaxone was 0.050 microg/ml. A once-per-day dosage regimen of ceftriaxone (50 mg/kg/dose) administered intramuscularly for 5 days was 100% effective in sterilizing tissue samples of C3H mice infected with this strain of B. burgdorferi, regardless of whether the mice were being treated concomitantly with a corticosteroid. Administration of the same five doses of ceftriaxone at 6-h intervals over just 24 h was also 100% effective. These experiments suggest that shorter courses of antibiotics than those currently recommended should be considered for study in patients with early uncomplicated Lyme disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.